Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

September Launch Eyed For Cephalon/J&J’s Sparlon

This article was originally published in The Pink Sheet Daily

Executive Summary

Cephalon plans to launch the attention deficit/hyperactivity disorder treatment Sparlon (modafinil) with partner Johnson & Johnson in September to take advantage of students returning to school, provided FDA approves the product by its Aug. 22 user fee date, Cephalon said

You may also be interested in...



Nuvigil May Be Further Delayed As FDA Reviews Side Effect Profile

Cephalon plans to submit information to FDA within “the next few weeks.”

Nuvigil May Be Further Delayed As FDA Reviews Side Effect Profile

Cephalon plans to submit information to FDA within “the next few weeks.”

Spar-Gone: Cephalon Drops Sparlon Following "Non-Approvable" Letter

FDA also extends user fee date for Nuvigil to December to analyze safety data.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel